ClinicalTrials.gg
Enrolling by invitationNCT07732101EX-BCSarcUpdated Nov 17, 2026

Exercise Intervention for Breast Cancer Patients With Sarcopenia

An interventional study of "Exercise for Muscle Health" Program in Sarcopenia and Breast Cancer, sponsored by Capital Medical University. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Capital Medical University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now Enrolling by invitationPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Sarcopenia with a site in China — 47 open to participants now, 52 under way, 4 of them phase 3. Sarcopenia · China.

Planned enrollment
28th of 52
104 · median 110
Started
2026
with 15 others
No phase
42 of 83
20 open now
Primary completion
2027-08
later than 29 of 51 live
Registered
77th of 83
by date
Lead sponsor
2 of 83
Capital Medical University

Among the 83 studies in Sarcopenia with a site in China, this one is the 28th largest by planned enrollment of the 52 interventional ones that give a count, is one of 16 that started in 2026, is one of 42 with no phase, reaches primary completion later than 29 of the 51 other live ones, and was the 77th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

47 of the 83 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Sarcopenia with a site in China, or all of them as a file.
02

Study summary

Sarcopenia is a common yet underrecognized complication in breast cancer survivors during rehabilitation, characterized by loss of muscle mass, reduced muscle strength, and impaired physical function, which adversely affects quality of life and long-term outcomes. Exercise has been identified as a promising non-pharmacological intervention for sarcopenia; however, evidence-based exercise programs specifically tailored for breast cancer patients with sarcopenia remain limited.

This study aims to develop and evaluate a 12-week exercise intervention program ("Exercise for Muscle Health") for breast cancer patients with sarcopenia during rehabilitation. A randomized controlled trial will be conducted to assess the effectiveness of the intervention. A total of 104 eligible participants will be randomly assigned in a 1:1 ratio to either the intervention group or the control group. The intervention group will receive a 12-week structured exercise program combined with health education, while the control group will receive routine rehabilitation care with general physical activity recommendations.

The primary outcomes include changes in appendicular skeletal muscle mass index (ASMI), handgrip strength, Short Physical Performance Battery (SPPB) score, and physical fitness (2-Minute Step Test and 30-second Chair-Stand Test). Secondary outcomes include sarcopenia-related knowledge, cancer self-efficacy, social support, anxiety, fatigue, and quality of life. Assessments will be conducted at baseline (T0), mid-intervention (week 6, T1), immediately post-intervention (week 12, T2), and 3 months post-intervention (T3).

The hypothesis is that the 12-week "Exercise for Muscle Health" program will significantly improve muscle mass, muscle strength, and physical function compared to routine care, and will be feasible, acceptable, and safe for breast cancer patients with sarcopenia during rehabilitation.

03

Conditions studied

  • Sarcopenia
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female, aged ≥18 years;

confirmed diagnosis of breast cancer, having completed primary treatment (surgery, chemotherapy, radiotherapy, etc.) and currently in the rehabilitation phase (≥3 months after treatment completion);

Meet sarcopenia diagnostic criteria assessed by trained researchers: for women aged ≥65 years, ASMI \< 0.57 and handgrip strength \< 18 kg; for women aged \<64 years, ASMI \< 0.63 and handgrip strength \< 20 kg;

Provide and voluntarily participate in the study;

Have basic communication and comprehension abilities.

Exclusion criteria

Exclusion Criteria:

History of psychiatric disorders or consciousness impairment;

Presence of exercise including severe cardiac, hepatic, or renal insufficiency, bone , or uncontrolled hypertension;

Major surgery or severe trauma within the past 3 months;

Involuntary weight loss >5% within the past 3 months, or presence of active progressive tumor burden (e.g., imaging evidence of significant metastasis or receiving palliative chemotherapy), suggesting tumor-driven cachexia;

Currently participating in other exercise intervention studies or having completed other exercise programs within the past 6 months;

Refusal of randomization.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Exercise Intervention Group

    A 12-week structured exercise intervention program consisting of two components: (1) Health education ; (2) Exercise intervention. The intervention is delivered by trained exercise specialists and supervised by the research team. Participants receive exercise diaries to record adherence.

    Behavioral: "Exercise for Muscle Health" Program

  • No intervention
    Control Group

    Participants receive routine rehabilitation care for breast cancer survivors, including: (1) Health education: provision of a breast cancer rehabilitation knowledge booklet covering lymphedema prevention, balanced diet, and weight management; (2) General physical activity advice: recommendation to engage in at least 150 minutes of moderate-intensity aerobic exercise (such as walking) per week, without provision of structured exercise prescriptions, standardized exercise instruction, intensity monitoring, or regular supervision.

Interventions

  • Behavioral"Exercise for Muscle Health" Program

    Participants receive routine rehabilitation care for breast cancer survivors, including: (1) provision of a breast cancer rehabilitation knowledge booklet covering lymphedema prevention, balanced diet, and weight management; (2) general physical activity advice recommending at least 150 minutes of moderate-intensity aerobic exercise (such as walking) per week, without structured exercise prescriptions, standardized instruction, intensity monitoring, or regular supervision.

06

What researchers measure

Primary outcomes

  1. Change in Appendicular Skeletal Muscle Mass Index (ASMI)

    Measured using InBody 120 body composition analyzer via bioelectrical impedance analysis (BIA). ASMI is calculated as appendicular skeletal muscle mass (kg) divided by BMI (kg/m²).

    Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)

  2. Handgrip Strength

    Measured using CAMRY electronic handgrip dynamometer (Model EH101). Participants stand with arms naturally, maximal grip strength is recorded twice for each hand, and the maximum value is used.

    Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)

  3. Short Physical Performance Battery (SPPB) Score

    SPPB assesses lower extremity function through three tests: balance test (side-by-side, semi-tandem, and tandem stands), 4-meter gait speed test, and 5-repetition chair-stand test. Total score ranges from 0 to 12, with higher scores indicating better physical function.

    Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)

  4. Physical Fitness

    Assessed by 2-Minute Step Test (2-MST) measuring cardiorespiratory endurance and 30-second Chair-Stand Test (CST) measuring lower limb muscle strength.

    Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)

Secondary outcomes

  1. Sarcopenia Disease Knowledge

    Measured using the Sarcopenia Disease Knowledge Scale developed by Tang et al. (2023), a self-reported 18-item scale covering etiology, clinical manifestations, hazards, diagnosis, and treatment. Likert 5-point scoring, higher scores indicate better knowledge.

    Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)

  2. Cancer Self-Efficacy

    Measured using the Chinese version of the Strategies Used by People to Promote Health (SUPPH), a 28-item self-reported scale. Higher scores indicate greater self-efficacy in cancer self-management.

    Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)

  3. Social Support

    Measured using the Social Support Rating Scale (SSRS) developed by Xiao Shuiyuan, a 10-item scale with three dimensions: objective support, subjective support, and utilization of support. Total score ranges from 12 to 66, with higher scores indicating higher social support.

    Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)

  4. Anxiety

    Measured using the Generalized Anxiety Disorder-7 (GAD-7) scale, a 7-item self-reported scale. Total score ranges from 0 to 21, with higher scores indicating more severe anxiety.

    Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)

  5. Cancer-Related Fatigue

    Measured using the Cancer Fatigue Scale (CFS), a 15-item scale with three dimensions: physical fatigue (7 items), affective fatigue (4 items), and cognitive fatigue (4 items). Likert 4-point scoring, total score ranges from 0 to 60

    Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)

  6. Change in Quality of Life

    Measured using the 36-item Short-Form Health Survey (SF-36), Chinese version. Eight dimensions: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. Each dimension scored 0-100, with higher scores indicating better health status.

    Time frame: Baseline (T0), Week 6 (T1), Week 12 (T2), 3 months post-intervention (T3)

07

Study locations

1 site
  • The Fifth Medical Center of Chinese PLA General Hospital (South Campus)
    Beijing, Beijing Municipality 100054, China
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared with other researchers. This decision is based on the following considerations: (1) the informed consent form signed by participants does not include provisions for sharing individual-level data with external parties; (2) sharing of such data is restricted by China's Personal Information Protection Law to ensure strict protection of patient privacy; and (3) the study resources are insufficient to establish a secure public data repository for IPD.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 11 months is below that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2027, last on Nov 17, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Apr 2027 → Aug 2027, last on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 28, 2026
StartActual
Sep 22, 2026
Primary completionEst.
Aug 30, 2027was Sep 2026
CompletionEst.
Aug 30, 2027was Apr 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 2, 2026
Start date
Sep 1, 2026→Sep 22, 2026 (actual)
moved 2 times, Oct 19, 2026 – Nov 2, 2026
Primary completion
Sep 20, 2026→Aug 30, 2027
moved 2 times, Oct 19, 2026 – Nov 17, 2026
Study completion
Apr 20, 2027→Aug 30, 2027
moved 2 times, Oct 19, 2026 – Nov 17, 2026
Contact
No study contact listed any more: removed l•••@ccmu.edu.cn · •••6128
Nov 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The Fifth Medical Center of Chinese PLA General Hospital (South Campus) · Beijing, ChinaContact removed l•••@ccmu.edu.cn · •••6128
Nov 2, 2026
Show all 3 updates
  1. Nov 17, 2026
    Primary completion May 30, 2027→Aug 30, 2027
    Study completion May 30, 2027→Aug 30, 2027
    + 1 other change: verification date
  2. Nov 2, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Oct 30, 2026→Sep 22, 2026 (now actual)
    Contact No study contact listed any more: removed l•••@ccmu.edu.cn · •••6128
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The Fifth Medical Center of Chinese PLA General Hospital (South Campus) · Beijing, ChinaContact removed l•••@ccmu.edu.cn · •••6128
  3. Oct 19, 2026
    Start date Sep 1, 2026→Oct 30, 2026
    Primary completion Sep 20, 2026→May 30, 2027
    Study completion Apr 20, 2027→May 30, 2027
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07732101
Responsible party
Xiao-qin Su (Principal Investigator of the Study, Capital Medical University) — Principal investigator
First posted
Jul 28, 2026
Start date
Sep 22, 2026
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion